{"id":"NCT02585778","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-23","primaryCompletion":"2017-04-03","completion":"2017-04-03","firstPosted":"2015-10-23","resultsPosted":"2018-05-17","lastUpdate":"2018-05-17"},"enrollment":517,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolaemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["Praluent","SAR236553","REGN727"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Lipid-Modifying Therapy (LMT)","otherNames":[]},{"type":"DRUG","name":"Antihyperglycemic Drug","otherNames":[]}],"arms":[{"label":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W","type":"EXPERIMENTAL"},{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objectives:\n\n* To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with hypercholesterolemia at high cardiovascular risk not adequately controlled on maximally tolerated LDL-C lowering therapy.\n* To evaluate the safety and tolerability of alirocumab in participants with diabetes treated with insulin.\n\nSecondary Objective:\n\nTo demonstrate that alirocumab was superior in comparison to placebo in its effects on other lipid parameters (i.e., measured LDL-C, non-high-density lipoprotein cholesterol \\[non-HDL-C\\], apolipoprotein B \\[Apo B\\], total cholesterol \\[TC\\], lipoprotein a \\[Lp(a)\\], high density lipoprotein cholesterol \\[HDL-C\\], triglyceride \\[TG\\] levels, triglyceride rich lipoproteins \\[TGRL\\], apolipoprotein A-1 \\[Apo A-1\\], apolipoprotein C-III \\[Apo C-III\\], and LDL particle number and size).","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T1DM Participants","deltaMin":-51.8,"sd":3.7},{"arm":"Placebo Q2W: T1DM Participants","deltaMin":-3.9,"sd":5.3},{"arm":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T2DM Participants","deltaMin":-48.2,"sd":1.6},{"arm":"Placebo Q2W: T2DM Participants","deltaMin":0.8,"sd":2.2}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":110,"countries":["United States","Austria","Belgium","France","Germany","Italy","Netherlands","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["33078867","31706300","28905478"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":344},"commonTop":["Nasopharyngitis"]}}